Inflammation in Alzheimer's disease: insights from immunotherapy.
暂无分享,去创建一个
[1] J. Trojanowski,et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. , 2013, Brain : a journal of neurology.
[2] C. Holmes,et al. Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization. , 2013, Brain : a journal of neurology.
[3] Nathan D. Kingery,et al. Scara1 deficiency impairs clearance of soluble Amyloid-β by mononuclear phagocytes and accelerates Alzheimer’s-like disease progression , 2013, Nature Communications.
[4] Keith A. Johnson,et al. CD33 Alzheimer’s disease locus: Altered monocyte function and amyloid biology , 2013, Nature Neuroscience.
[5] Bradley T. Hyman,et al. Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta , 2013, Neuron.
[6] G. Mead,et al. Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia , 2013, Alzheimer's & Dementia.
[7] L. Tran,et al. Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease , 2013, Cell.
[8] Joshua H. K. Tam,et al. A dual magnetic resonance imaging/fluorescent contrast agent for Cathepsin-D detection. , 2013, Contrast media & molecular imaging.
[9] Christine Van Broeckhoven,et al. Genetic insights in Alzheimer's disease , 2013, The Lancet Neurology.
[10] A. Singleton,et al. TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.
[11] A. Hofman,et al. Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.
[12] E. Karran. Current status of vaccination therapies in Alzheimer's disease , 2012, Journal of neurochemistry.
[13] K. Blennow,et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. , 2012, Archives of neurology.
[14] Keith A. Johnson,et al. THE A4 TRIAL: ANTI-AMYLOID TREATMENT OF ASYMPTOMATIC ALZHEIMER'S DISEASE , 2012, Alzheimer's & Dementia.
[15] E. Planel,et al. Is general anaesthesia a risk factor for Alzheimer's? Clues from biomarkers , 2012, Alzheimer's & Dementia.
[16] N. Tabet,et al. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. , 2012, The Cochrane database of systematic reviews.
[17] B. Zlokovic. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders , 2011, Nature Reviews Neuroscience.
[18] H. Paulson,et al. Genetics of Dementia , 2011, Seminars in neurology.
[19] Clifford R. Jack,et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup , 2011, Alzheimer's & Dementia.
[20] D. Wald,et al. Serum homocysteine and dementia: Meta-analysis of eight cohort studies including 8669 participants , 2011, Alzheimer's & Dementia.
[21] J. Morris,et al. Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.
[22] C. Holmes,et al. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer’s disease , 2010, Acta Neuropathologica.
[23] V. Perry,et al. Microglia in neurodegenerative disease , 2010, Nature Reviews Neurology.
[24] Martin Rossor,et al. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study , 2008, Neurobiology of Disease.
[25] Seth Love,et al. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.
[26] Nick C Fox,et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.
[27] Nick C Fox,et al. Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease , 2005, Neurology.
[28] B. Miller,et al. CME Practice parameter : Diagnosis of dementia ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .
[29] C. Plata-salamán,et al. Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.
[30] R. Motter,et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.
[31] J. Loike,et al. Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils , 1996, Nature.
[32] J. Hardy,et al. Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.
[33] J. Winn,et al. Brain , 1878, The Lancet.
[34] Kewei Chen,et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. , 2011, Journal of Alzheimer's disease : JAD.
[35] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[36] J. Loike,et al. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. , 1996, Nature.